Logo image of GRCE

GRACE THERAPEUTICS INC (GRCE) Stock Fundamental Analysis

NASDAQ:GRCE - Nasdaq - US00439U1043 - Common Stock - Currency: USD

2.87  -0.02 (-0.69%)

After market: 3 +0.13 (+4.53%)

Fundamental Rating

3

Overall GRCE gets a fundamental rating of 3 out of 10. We evaluated GRCE against 194 industry peers in the Pharmaceuticals industry. GRCE has a great financial health rating, but its profitability evaluates not so good. GRCE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRCE had negative earnings in the past year.
In the past year GRCE has reported a negative cash flow from operations.
In the past 5 years GRCE always reported negative net income.
GRCE had a negative operating cash flow in each of the past 5 years.
GRCE Yearly Net Income VS EBIT VS OCF VS FCFGRCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -13.29%, GRCE is doing good in the industry, outperforming 65.98% of the companies in the same industry.
GRCE has a Return On Equity of -14.36%. This is in the better half of the industry: GRCE outperforms 74.23% of its industry peers.
Industry RankSector Rank
ROA -13.29%
ROE -14.36%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
GRCE Yearly ROA, ROE, ROICGRCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCE Yearly Profit, Operating, Gross MarginsGRCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for GRCE has been increased compared to 1 year ago.
GRCE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRCE Yearly Shares OutstandingGRCE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GRCE Yearly Total Debt VS Total AssetsGRCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

GRCE has an Altman-Z score of -0.29. This is a bad value and indicates that GRCE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.29, GRCE perfoms like the industry average, outperforming 51.03% of the companies in the same industry.
GRCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACCN/A
GRCE Yearly LT Debt VS Equity VS FCFGRCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 11.77 indicates that GRCE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.77, GRCE belongs to the top of the industry, outperforming 84.54% of the companies in the same industry.
A Quick Ratio of 11.77 indicates that GRCE has no problem at all paying its short term obligations.
The Quick ratio of GRCE (11.77) is better than 84.54% of its industry peers.
Industry RankSector Rank
Current Ratio 11.77
Quick Ratio 11.77
GRCE Yearly Current Assets VS Current LiabilitesGRCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GRCE have decreased strongly by -53.11% in the last year.
EPS 1Y (TTM)-53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.63% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.29%
EPS Next 2Y24.7%
EPS Next 3Y33.74%
EPS Next 5Y30.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCE Yearly Revenue VS EstimatesGRCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
GRCE Yearly EPS VS EstimatesGRCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRCE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCE Price Earnings VS Forward Price EarningsGRCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCE Per share dataGRCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as GRCE's earnings are expected to grow with 33.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.7%
EPS Next 3Y33.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRCE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRACE THERAPEUTICS INC

NASDAQ:GRCE (8/1/2025, 8:00:00 PM)

After market: 3 +0.13 (+4.53%)

2.87

-0.02 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-24 2025-06-24/amc
Earnings (Next)08-07 2025-08-07
Inst Owners30.04%
Inst Owner ChangeN/A
Ins Owners4.9%
Ins Owner ChangeN/A
Market Cap39.69M
Analysts82.22
Price Target12.11 (321.95%)
Short Float %0.73%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)79.08%
Min EPS beat(2)40.72%
Max EPS beat(2)117.45%
EPS beat(4)3
Avg EPS beat(4)50.15%
Min EPS beat(4)-6.26%
Max EPS beat(4)117.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.35%
EPS NQ rev (1m)38.25%
EPS NQ rev (3m)38.25%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0
BVpS4.82
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.29%
ROE -14.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 200%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.77
Quick Ratio 11.77
Altman-Z -0.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.56%
EPS Next Y35.29%
EPS Next 2Y24.7%
EPS Next 3Y33.74%
EPS Next 5Y30.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.02%
EBIT Next 3Y7.18%
EBIT Next 5YN/A
FCF growth 1Y22.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.48%
OCF growth 3YN/A
OCF growth 5YN/A